Targeted gene silencing in the nervous system with CRISPR-Cas13
Powell et al. (2022). Sci AdvResearch
Cas13 had silenced genes in cultured cells but not in the nervous system. AAV-delivered RfxCas13d lowered SOD1 in the spinal cord of G93A-SOD1 mice, extending disease duration by about 33%, and lowered HTT protein by about 60% in R6/2 mouse striatum.
Parts & designs used
Author abstract
Cas13 nucleases are a class of programmable RNA-targeting CRISPR effector proteins that are capable of silencing target gene expression in mammalian cells. Here, we demonstrate that RfxCas13d, a Cas13 ortholog with favorable characteristics to other family members, can be delivered to the mouse spinal cord and brain to silence neurodegeneration-associated genes. Intrathecally delivering an adeno-associated virus vector encoding an RfxCas13d variant programmed to target superoxide dismutase 1 (SOD1), a protein whose mutation can cause amyotrophic lateral sclerosis, reduced SOD1 mRNA and protein in the spinal cord by >50% and improved outcomes in a mouse model of the disorder. We further show that intrastriatally delivering an RfxCas13d variant programmed to target huntingtin (HTT), a protein whose mutation is causative for Huntington’s disease, led to a ~50% reduction in HTT protein in the mouse brain. Our results establish RfxCas13d as a versatile platform for knocking down gene expression in the nervous system.
Identifiers & revision
DOI 10.1126/sciadv.abk2485OpenAlex W4206365019PubMed 35044815
